These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22016088)

  • 1. Rare disease patient groups as clinical researchers.
    Polich GR
    Drug Discov Today; 2012 Feb; 17(3-4):167-72. PubMed ID: 22016088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scientists and healers: toward collaborative research partnerships.
    Levin J
    Explore (NY); 2008; 4(5):302-10. PubMed ID: 18775400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research performance of centers of expertise for rare diseases--the influence of network integration, internal resource access and operational experience.
    Hannemann-Weber H; Kessel M; Schultz C
    Health Policy; 2012 May; 105(2-3):138-45. PubMed ID: 22401748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients often go without effective new treatments, especially in rare disease patient populations where profit potential is limited.
    Bloom BE
    Contemp Clin Trials; 2011 Mar; 32(2):151-2. PubMed ID: 21238613
    [No Abstract]   [Full Text] [Related]  

  • 5. Outlook: finding improved medicines: the role of academic-industrial collaboration.
    Chin-Dusting J; Mizrahi J; Jennings G; Fitzgerald D
    Nat Rev Drug Discov; 2005 Nov; 4(11):891-7. PubMed ID: 16247439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges of rare disease research: limited patients and competing priorities.
    Ragni MV; Moore CG; Bias V; Key NS; Kouides PA; Francis CW;
    Haemophilia; 2012 May; 18(3):e192-4. PubMed ID: 21910791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clusters in the biopharmaceutical industry: toward a new method of analysis.
    Erden Z; von Krogh G
    Drug Discov Today; 2011 May; 16(9-10):450-6. PubMed ID: 21397037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery.
    Wood J; Sames L; Moore A; Ekins S
    Drug Discov Today; 2013 Nov; 18(21-22):1043-51. PubMed ID: 23968993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of research collaborations and consortia in rare cancers.
    Blay JY; Coindre JM; Ducimetière F; Ray-Coquard I
    Lancet Oncol; 2016 Feb; 17(2):e62-e69. PubMed ID: 26868355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers: What can we learn from clinical research?
    Eichler HG; Kong SX; Grégoire JP
    Eur J Health Econ; 2006 Jun; 7(2):129-35. PubMed ID: 16485122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deals landscape: notable deals in the pharmaceutical industry in the first quarter of 2008.
    Shumoogam J; Al-Shamahi A
    IDrugs; 2008 May; 11(5):351-5. PubMed ID: 18465677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research considerations when studying disasters.
    Cox CW
    Crit Care Nurs Clin North Am; 2008 Mar; 20(1):111-9, viii. PubMed ID: 18206591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategic groups in the biopharmaceutical industry: implications for performance.
    Erden Z; von Krogh G; Nytorp C; Hultberg M
    Drug Discov Today; 2009 Aug; 14(15-16):726-30. PubMed ID: 19416760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health research in Ethiopia--past, present and suggestions on the way forward.
    Gaym A
    Ethiop Med J; 2008 Jul; 46(3):287-308. PubMed ID: 19271395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A guide for success as a clinical investigator.
    Provenzale D
    Gastroenterology; 2012 Mar; 142(3):418-21. PubMed ID: 22266151
    [No Abstract]   [Full Text] [Related]  

  • 16. A patient-researcher partnership for rare cancer research.
    Staniszewka S
    Nat Med; 2020 Feb; 26(2):164-165. PubMed ID: 32042195
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug discovery: new models for industry-academic partnerships.
    Tralau-Stewart CJ; Wyatt CA; Kleyn DE; Ayad A
    Drug Discov Today; 2009 Jan; 14(1-2):95-101. PubMed ID: 18992364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Creating reflective spaces: interactions between philosophers and biomedical scientists.
    de Melo-Martín I
    Perspect Biol Med; 2009; 52(1):39-47. PubMed ID: 19168943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing gene and cell therapies for rare diseases: an opportunity for synergy between academia and industry.
    Mavilio F
    Gene Ther; 2017 Sep; 24(9):590-592. PubMed ID: 28485723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bridging the Academia/Industry Chasm: Proposed Solutions.
    Beninger P; Boumil M; Salem D; Getz K; Klapholz H; Curfman GD; Jotwani R; Berman H
    J Clin Pharmacol; 2016 Dec; 56(12):1457-1460. PubMed ID: 27149908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.